Eli Lilly

NIH launches collaborative program to spur therapeutic development

Friday, May 4, 2012 08:02 AM

The National Institutes of Health (NIH) has unveiled a collaborative program, Discovering New Therapeutic Uses for Existing Molecules, that will match researchers with a selection of pharmaceutical industry compounds to help scientists explore new treatments for patients.

More... »

Report: Pharmaceutical market grew by 5.3% in 2011

Friday, April 20, 2012 12:29 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, found that in 2011, the global pharmaceutical market, in dollar terms, benefitted significantly from positive currency effects.

More... »

Vanda lands exclusive world-wide license for VLY-686 from Lilly

Monday, April 16, 2012 11:40 AM

Vanda Pharmaceuticals, a biopharmaceutical company focused on central nervous system disorders, has acquired an exclusive world-wide license from Eli Lilly to develop and commercialize a small molecule neurokinin 1 receptor (NK-1R) antagonist for all human indications.

More... »

FDA approves Lilly’s Amyvid to detect Alzheimer's

Monday, April 9, 2012 11:53 AM

The FDA has approved Amyvid, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques associated with Alzheimer’s Disease and other cognitive decline, according to Eli Lilly and Avid Radiopharmaceuticals, a wholly owned subsidiary of Lilly.

More... »

Daiichi forms diabetes alliance with NGM Biopharma

Friday, March 30, 2012 03:07 PM

Tokyo-based Daiichi Sankyo has formed a partnership with San Francisco-based NGM Biopharmaceuticals to research and develop new treatments for diabetes.

More... »

Europe approves Byetta with basal insulin for T2D

Monday, March 26, 2012 02:47 PM

The European Commission has granted Amylin Pharmaceuticals and Eli Lilly marketing authorization for Byetta (exenatide twice-daily) as an adjunctive therapy to basal insulin for the treatment of type 2 diabetes (T2D).

More... »

Academic-industry collaboration seeks new drugs, treatments for autism

Monday, March 19, 2012 02:41 PM

An international consortium of scientists led by Roche, King's College London and Autism Speaks is collaborating on one of the largest ever academic-industry research projects, to find new methods for the development of drugs for autism spectrum disorder (ASD), which affects 1% of children worldwide.

More... »

Hovione appoints Minchom vice president

Wednesday, March 14, 2012 09:14 AM

Dr. Colin Minchom has been appointed as vice president of Hovione’s particle design business unit. He will be based in East Windsor, N.J., and report to Guy Villax, CEO of Hovione.

More... »

Dendreon appoints three to executive team

Wednesday, March 14, 2012 09:10 AM

Seattle, Wash.-based Dendreon has appointed three new members to its executive team:

More... »

Lilly introduces global 'Innovation Starts Here' initiative

Thursday, March 1, 2012 06:02 AM

Eli Lilly has launched a global Innovation Starts Here initiative, which supports Lilly's commitment to speeding the delivery of innovative new medicines to patients around the world.

More... »